CAS: 562-10-7; Butanedioic Acid, Compd. Withn,N-Dimethyl-2-[1-Phenyl-1-(2-Pyridinyl)Ethoxy]Ethanamine (1:1)Other Ca Index Names:Ethanamine, N,N-Dimethyl-2-[1-Phenyl-1-(2-Pyridinyl)Ethoxy]-,Butanedioate (1:1)

该化合物是一种该化合物是一种甲胺受体对抗剂,有效减轻过敏反应和失眠症状; 其氨酸盐形式可以提高溶解性和生物利用率,确保持续的药用动力性能; 该化合物由于能够抑制咳嗽反应,所以广泛用于短期睡眠援助配方和冷/流感药物的辅助剂; 主要优势包括快速采取行动和可预测的代谢清除,主要是通过肝道. 其有据可查的受控剂量中的安全特征使得它成为过量睡眠和过敏治疗的标准.

结构式图片

欧盟法规

ECHA物质ECHA物质C&L通报REACH预注册

上下游产品

succinic acid doxylamine iodobenzene 2-acetylpyridine2-[1-(dimethylammonioethoxy)-1-phenylethyl]pyridinium tetrachlor°Cuprate(II) [2-(1-(dimethylammonioethoxy)-1-phenylethyl)pyridinium] tetrachlor°Cobaltate(II) [2-(1-(dimethylammonioethoxy)-1-phenylethyl)pyridinium] tetrachlorozincate(II)

合成工艺路线路线简述

    碘苯置于盐酸,碘,Sodium Amide,Magnesium体系中,用 5,5-Dimethyl-1,3-Cyclohexadiene,乙醚,水,丙酮 作为反应溶剂,化学反应 24.5H,反应生成 琥珀酸多西拉敏
    参考文献:一种琥珀酸多西拉敏的制备方法
    标题:一种琥珀酸多西拉敏的制备方法
    摘要:本发明涉及一种琥珀酸多西拉敏的制备方法,首先选用碘苯和镁反应生成的grignard试剂与2-乙酰吡啶反应反应生成2-吡啶基苯基甲基甲醇,经重结晶纯化,然后2-吡啶基苯基甲基甲醇依次同氨基钠和2-二甲氨基氯乙烷反应,得到多西拉敏,最后多西拉敏与琥珀酸成盐反应得到琥珀酸多西拉敏.本制备工艺反应效率高,成本较低,适合工业化大生产.

    海关参考信息

    专利信息


    专利号:US-2022125711-A1
    优先权日:2020-10-23
    标题 :Cannabinoid-containing oral thin film formulations
    发明人:BAJAJ AKHIL; WEBB SKYLER; HOOSEIN SHEHZAD; RASHKOW ANDREW
    权利人:JDEM PROPERTIES LLC
    摘要:The methods disclosed herein permit the synthesis of cannabinoid-containing oral thin film (OTF) strips that also contain caffeine or multiple additional active ingredients. Selection of film forming agents based on water usage coupled with low temperature mixing and low temperature drying may in various embodiments permit the incorporation of up to five additional ingredients into a cannabinoid containing OTF product.

    专利号:CN-114524765-A
    优先权日:2021-12-27
    标题 :A kind of method for base-catalyzed synthesis of doxylamine succinate

    专利号:US-2005053642-A1
    优先权日:2000-08-23
    标题:Biocompatible materials
    发明人:ULBRICHT MATHIAS; THOM VOLKMAR; JANKOVA KATJA; ALTANKOV GEORGE; JONSSON GUNNAR
    摘要:The present invention teaches a novel approach of creating biocmpatible surfaces, said surfaces being capable of functionally interact with biological material. SAid biocompatible surfaces comrise at least two comonents, such as a hydrophobic substratum and a macromolecule of hydrophilic nature, which, in a cooperativity, form together the novel biocoompatible surfaces. The novel approach is ased on contacting said hydrophobic substratum with a laterally patterned monomolecular layer of said hydrophilic and flexible macromolecules, exhibiting a pronounced excluded volume. The htus formed two component surface is, in respect to polarity and morphology, a molecularly heterogeneous surface. Structural features of said macromolecular monolayer (as e.g. the layer thickness or its lateral density) are determined by: i) the structural features of the layer forming macromolecules (as e.g. their MW or their molecular architecture) and ii) the method of creating said monomolecular layer (as e.g. by physi- or chemisorbing, or by chemically binding said macromolecules). The structural features of the layer forming macromolecules(s) is in turn determined by synthesis. AMount and conformation and thus also biological activity of biological material (as e.g. polypeptides) which contact the novel biocompatible surface, is determined and maintained by the cooperative action of the underlying hydrophobic substratum and the macromolecular layer. In this way it becomes possible to maintain and control biological interactions between said contacted polypeptides and other biological compounds as e.g. cells, antibodies and the like. Consequently, the present invention aims to reduce and/or eliminate the deactivation and/or denaturation associated with the contacting of polypeptides and/or other biological material to a hydrophobic substratum surface.

    专利号:CN-110498764-B
    优先权日:2019-09-25
    标 题:A kind of synthesis method of doxylamine succinate
    深圳市祥福林化工技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.happypharm.cn
    电话: 0086(755)8214-7376👤
    📞深圳市祥福林化工技术有限公司 ⚠️参考联系方式

    销售电话:0086(755)8214-7376
    邮箱:info@happychem.cn
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Pope E, Maltepe C, Koren G. Comparing pyridoxine and doxylamine succinate-pyridoxine HCl for nausea and vomiting of pregnancy: A matched, controlled cohort study. J Clin Pharmacol. 2015 Jul;55(7):809-14. doi: 10.1002/jcph.480. Epub 2015 Mar 27. doi: 10.2147/IJWH.S46653. eCollection 2014. Review.
    3: Koren G, Vranderick M, Gill SK, Macleod S. Sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate-pyridoxine hydrochloride; implications for pharmacotherapy in pregnancy. J Clin Pharmacol. 2013 Dec;53(12):1268-76. doi: 10.1002/jcph.184. Epub 2013 Oct 10. doi: 10.1310/hpj4809-762.
    5: Nulman I, Koren G. Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age. Can J Clin Pharmacol. 2009 Fall;16(3):e400-6. Epub 2009 Oct 29. Review. German. French. doi: 10.1016/j.talanta.2006.02.023. Epub 2006 Mar 20. doi: 10.4103/0250-474X.44607.

    合成参考文献


    摘要:Journal of the American Pharmaceutical Association, Scientific Edition., 37(311), 1948
    摘要:Journal of Laboratory and Clinical Medicine., 33(325), 1948
    参考文献:10.1007/s001050050915
    摘要:Brockow K, Abeck D, Ring J. [Systemic therapy in the treatment concept of atopic eczema. Reliable treatment methods and experimental developments]. Hautarzt. 1999 May;50(5):323–9. doi: 10.1007/s001050050915.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知